What is the stock price of genetic technologies?
Since then, GENE stock has decreased by 10.2% and is now trading at $2.12. View which stocks have been most impacted by COVID-19. Who are Genetic Technologies' key executives? Who are some of Genetic Technologies' key competitors?
What are the top 5 genetic testing stocks?
5 Top Genetic Testing Stocks. 1. Exact Sciences (NASDAQ: EXAS) Market cap: US$18.83 billion. 2. Natera (NASDAQ: NTRA) 3. Invitae ( NYSE: NVTA) 4. NeoGenomics Laboratories (NASDAQ: NEO)
Is applied Genetic Technologies (AGT) a good stock to buy?
Applied Genetic Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $21.00, Applied Genetic Technologies has a forecasted upside of 955.3% from its current price of $1.99.
Where can I buy shares of gene?
Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is GENE stock a buy?
Is Genetic Technologies stock a buy? According to analysts the answer is an unequivocal yes. The GENE price target from Wall Street is almost 10x higher than where the stock is currently trading. Clearly there is optimism about future pipeline successes.
Will GENE stock go up?
Based on our forecasts, a long-term increase is expected, the "GENE" stock price prognosis for 2027-07-21 is 3.276 USD. With a 5-year investment, the revenue is expected to be around +127.31%. Your current $100 investment may be up to $227.31 in 2027.
Why was trading halted on GENE?
Trading Halt on ASX exchange requested by the company : Company requested a trading halt in anticipation of an udpate regarding the Company's COVID-19 Serious Disease Risk Test.
What is the best DNA stock?
Illumina. Illumina is the industry leader in using short-read sequencing technology, which breaks DNA into short segments to aid in analysis for genetic research, testing, and medical treatment. ... Pacific Biosciences of California. ... Exact Sciences. ... Invitae. ... Fulgent Genetics. ... Intellia Therapeutics. ... CRISPR Therapeutics.
Should I sell AGTC stock?
Is Applied Genetic Technologies Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: AGTC) stock is to Strong Buy AGTC stock.
What happened to spark Therapeutics stock?
PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that NASDAQ has halted trading of its common stock.
When did spark Therapeutics go public?
PHILADELPHIA, Dec. 14, 2015 (GLOBE NEWSWIRE) — Spark Therapeutics, Inc.
Is spark Therapeutics publicly traded?
PHILADELPHIA, Jan. 30, 2015 /PRNewswire/ — Spark Therapeutics announced today the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts.
How has Genetic Technologies' stock performed in 2022?
Genetic Technologies' stock was trading at $1.88 at the start of the year. Since then, GENE shares have decreased by 34.6% and is now trading at $1...
Who are Genetic Technologies' key executives?
Genetic Technologies' management team includes the following people: Mr. Simon Morriss , Chief Exec. Officer Mr. Michael Tonroe ACA , B.Sc., Bsc...
Who are some of Genetic Technologies' key competitors?
Some companies that are related to Genetic Technologies include Black Diamond Therapeutics (BDTX) , SAB Biotherapeutics (SABS) , Codiak BioScien...
What other stocks do shareholders of Genetic Technologies own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogen...
What is Genetic Technologies' stock symbol?
Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."
Who are Genetic Technologies' major shareholders?
Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Group One Trading L.P....
Which major investors are selling Genetic Technologies stock?
GENE stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., and Simplex Trading LLC.
How do I buy shares of Genetic Technologies?
Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Genetic Technologies' stock price today?
One share of GENE stock can currently be purchased for approximately $1.23.
About Genetic Technologies
Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.
Top genetic sequencing companies
How has Genetic Technologies' stock price been impacted by Coronavirus?
1. Illumina
These are some of the genetic sequencing companies investors should have on their watch list:
2. Pacific Biosciences of California
Since its founding in 1998, Illumina has become an industry leader, with more than 90% of the global sequencing market and an installed base of more than 17,000 sequencing systems.
3. 10x Genomics
Pacific Biosciences of California (aka, PacBio) is pioneering long-read sequencing technology, which uses longer DNA segments to map the whole genome. Long-read sequencing can uncover parts of the genome missed by short-read sequencing. Although the Human Genome Project was declared “complete” in 2003, it missed about 8% of the genome.
4. Bionano Genomics
10x was founded in 2012 to “build solutions for scientific discovery that reveal and address the true complexities of biology and disease.” The company manufactures instruments, consumables, and software for whole genome sequencing, exome sequencing, and single cell transcriptomics.
Investing in genetic sequencing stocks
Bionano was founded in 2003 with a mission “committed to the relentless pursuit of the truth in genomics.” The company is using its optical genome mapping technology to perform structural variant detection for cancer research and precision medicine.
